- CSR Summary Not yet available
- NCT02165397
- Primary Citation Trial has yet to be published
Trial Information
Generic NameIbrutinibProduct NameIMBRUVICA®Therapeutic AreaCancers and Other NeoplasmsEnrollment181% FemaleN/A% WhiteN/A
Product ClassKinase InhibitorsSponsor Protocol NumberPCYC-1127-CAData PartnerJohnson & JohnsonCondition StudiedNeoplasmsMean/Median Age (Years)N/A
Supporting Documentation
- Collected Datasets Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0828 : Prognostic Impacts of Clinical and Molecular Characteristics of Patients with Hematologic Malignancy and Potential Mechanisms
- 2023-5247 : Identifying Prognostic and Predictive Factors for Causal Exposure-Response Analysis of Ibrutinib in treatment of non-Hodgkin Lymphoma
- 2022-4928 : Ibrutinib plus rituximab versus ibrutinib monotherapy in patients with Waldenstrm macroglobulinemia: A pooled analysis of prospective studies